Early research shows these drugs are just as powerful in this life stage, and combining them with hormone replacement therapy (HRT) may make them even more effective
Book a consult or reach out to us today!
Oral administration of PF-06882961 shows evidence of glucose-lowering in healthy human study participants PF-06882961 was selected as a candidate for clinical studies based on its in vitro and in vivo pharmacologic and disposition profile, including potent agonism of the GLP-1R, preclinical disposition attributes (e.g., low metabolic CL int in human hepatocytes), good safety margins versus the hERG channel (IC 50 = 4.3 M, Table S4) and broad panel screening (Table S8), and selectivity versus related class B GPCRs (Table S9)
A structured, evidence-based regimen that supports each stage of the migraine cycle promotes greater neurological resilience
Liu Y, Song Z, Liu Y, Ma X, Wang W, Ke Y, et al
Bryan Gawley, delivers a thoughtful fusion of aesthetic refinement and metabolic wellness
